Sonic Healthcare Limited表示，瑞士方面的监管政策变动，叠加英国Hwe合约整合时间线的拉长，预计将对2027财年的EBITDA增长产生不利影响。
这家医疗诊断巨头正面临多重挑战。一方面，瑞士监管框架的调整带来了新的合规成本与运营压力；另一方面，其在英国Hwe合约的整合进程也较原计划更为漫长。两股力量的交织，使得公司对未来业绩的预期不得不趋于谨慎。
公司管理层指出，这些因素的叠加效应将在2027财年逐步显现，届时EBITDA的增速或将明显放缓。尽管当前尚未给出具体的量化指引，但市场的关注焦点已迅速转向这一潜在风险。
对投资者而言，这意味着需要重新评估该股的中期增长逻辑。毕竟，监管环境的变化和整合进度的延误，往往并非短期能轻易化解的变数。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.